期刊
TRANSPLANTATION
卷 98, 期 4, 页码 370-379出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000000243
关键词
Regulatory T cells; FOXP3; Transplantation; Hemodialysis; Interleukin-17; Clinical trial; Subpopulation
资金
- National Institute for Health Research
- Medical Research Council
- Academy of Medical Sciences
- Wellcome Trust
- ONE Study
- British Heart Foundation
- Kidney Patients' Association
- Guy's and St Thomas' Charity
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- British Heart Foundation [RG/13/12/30395] Funding Source: researchfish
- Medical Research Council [MR/J006742/1] Funding Source: researchfish
- National Institute for Health Research [CL-2008-17-003] Funding Source: researchfish
Clinical tolerance induction to permit minimization or cessation of immunosuppressive drugs is one of the key research goals in solid organ transplantation. The use of ex vivo expanded or manipulated immunologic cells, including CD(4+)CD25(hi)FOXP3(+) regulatory T cells (Tregs), to achieve this aim is already a reality, with several trials currently recruiting patients. Tregs are a highly suppressive, nonredundant, population of regulatory cells that prevent the development of autoimmune diseases in mammals. Data from transplanted humans and animal models support the notion that Tregs can mediate both induction and adoptive transfer of transplantation tolerance. However, human Tregs are highly heterogeneous and include subpopulations with the potential to produce the proinflammatory cytokine interleukin-17, which has been linked to transplant rejection. Tregs are also small in number in the peripheral circulation, thus they require ex vivo expansion before infusion into man. Selection of the most appropriate Treg population for cell therapy is, therefore, a critical step in ensuring successful clinical outcomes. In this review, we discuss Treg subpopulations, their subdivision based on nonmutually exclusive criteria of origin, expression of immunologic markers and function, availability in the peripheral blood of patients awaiting transplantation, and their suitability for programs of cell-based therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据